EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the E Prostanoid Receptor EP4 Mitigates Cardiac Fibrosis Induced by β‐Adrenergic Activation

Hu Xu iD, Xiuhui Mao, Yali Wang, Chunhua Zhu, Bo Liang, Yihang Zhao, Mengfei Zhou, Lan Ye, Mengting Hong, Huishu Shao, Yashuo Wang, Haonan Li und 5 weitere

Advanced Science · 2025-03 · 12 (12)

DOI: 10.1002/advs.202413324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 07.02.2025. Verfasst von Hu Xu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Wuhu Hospital, East China Normal University, Shanghai, 200241, China. Hauptthemen laut MEDLINE: Receptors, Prostaglandin E, EP4 Subtype, Fibrosis, Receptors, Adrenergic, beta. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Training program of key department of Pudong health system.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sustained β‐adrenergic activation induces cardiac fibrosis characterized by excessive deposition of extracellular matrix (ECM). Prostaglandin E 2 (PGE 2 ) receptor EP4 is essential for cardiovascular homeostasis. This study aims to investigate the roles of cardiomyocyte (CM) and cardiac fibroblast (CF) EP4 in isoproterenol (ISO)‐induced cardiac fibrosis. By crossing the EP4 f/f mice with α‐MyHC‐Cre or S100A4‐Cre mice, this work obtains the CM‐EP4 knockout (EP4 f/f ‐α‐MyHC Cre+ ) or CF‐EP4 knockout (EP4 f/f ‐S100A4 Cre+ ) mice. The mice of both genders are subcutaneously injected with ISO (5 mg kg −1 day −1 ) for 7 days. Compared to the control mice, both EP4 f/f ‐α‐MyHC Cre+ and EP4 f/f ‐S100A4 Cre+ mice show a significant improvement in cardiac diastolic function and fibrosis as assessed by echocardiography and histological staining, respectively. In the CMs, inhibition of EP4 suppresses ISO‐induced TGF‐β1 expression via blocking the cAMP/PKA pathway. In the CFs, inhibition of EP4 reversed TGF‐β1‐triggers production of ECM via preventing the formation of the TGF‐β1/TGF‐β receptor complex and blocks CF proliferation via suppressing the ERK1/2 pathway. Furthermore, double knockout of the CM‐ and CF‐EP4 or administration of EP4 antagonist, grapiprant, markedly improves ISO‐induced cardiac diastolic dysfunction and fibrosis. Collectively, this study demonstrates that both CM‐EP4 and CF‐EP4 contribute to β‐adrenergic activation‐induced cardiac fibrosis. Targeting EP4 may offer a novel therapeutic approach for cardiac fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Prostaglandin E, EP4 SubtypeFibrosisReceptors, Adrenergic, betaAnimalsMiceIsoproterenolMyocytes, CardiacMice, KnockoutMaleMyocardiumFibroblastsAdrenergic beta-Agonists

Stichwörter der Autor:innen

EP4 receptorTGF‐β signalingcardiac fibroblastcardiac fibrosiscardiomyocyteisoproterenol

Substanzen

Receptors, Prostaglandin E, EP4 SubtypeIsoproterenolPtger4 protein, mouseReceptors, Adrenergic, betaAdrenergic beta-Agonists

Autor:innen und Institutionen

  • Wuhu Hospital, East China Normal University, Shanghai, 200241, China.
  • Health Science Center, East China Normal University, Shanghai, 200241, China.
  • Advanced Institute for Medical Sciences, Dalian Medical University, Dalian, 116044, China.
  • MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian University of Technology, Dalian, 116024, China.
  • Department of Nephrology, Pudong New District Punan Hospital, Shanghai, 200125, China.

ORCID-Profile: Hu Xu, Xiaoyan Zhang

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Training program of key department of Pudong health system
  • National Key Research and Development Program of China

Zitieren

APA

Xu, H., Mao, X., Wang, Y., Zhu, C., Liang, B., Zhao, Y., Zhou, M., Ye, L., Hong, M., Shao, H., Wang, Y., Li, H., Qi, Y., Yang, Y., Chen, L., Guan, Y., & Zhang, X. (2025). Targeting the E Prostanoid Receptor EP4 Mitigates Cardiac Fibrosis Induced by β‐Adrenergic Activation. Advanced Science, 12(12). https://doi.org/10.1002/advs.202413324

Vancouver

Xu H, Mao X, Wang Y, Zhu C, Liang B, Zhao Y, et al. Targeting the E Prostanoid Receptor EP4 Mitigates Cardiac Fibrosis Induced by β‐Adrenergic Activation. Advanced Science. 2025;12(12). doi:10.1002/advs.202413324

BibTeX
@article{Xu2025,
  author = {Xu, Hu and Mao, Xiuhui and Wang, Yali and Zhu, Chunhua and Liang, Bo and Zhao, Yihang and Zhou, Mengfei and Ye, Lan and Hong, Mengting and Shao, Huishu and Wang, Yashuo and Li, Haonan and Qi, Yinghui and Yang, Yongliang and Chen, Lihong and Guan, Youfei and Zhang, Xiaoyan},
  title = {Targeting the E Prostanoid Receptor EP4 Mitigates Cardiac Fibrosis Induced by β‐Adrenergic Activation},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {12},
  doi = {10.1002/advs.202413324}
}
Kostenlos starten →